docetaxel + paclitaxel + pemetrexed

This is a combination of three chemotherapeutic agents used in the treatment of non-small cell lung cancer (NSCLC). Docetaxel and paclitaxel are both taxanes that work by inhibiting cell division, while pemetrexed is a folate analog that inhibits enzymes used in purine and pyrimidine synthesis. These drugs are typically used in sequence rather than simultaneously, with pemetrexed often used in first-line treatment (with platinum agents) and docetaxel in second-line treatment after failure of first-line therapy. Studies have shown that the sequence of administration can affect both efficacy and toxicity profiles.